Management of infection among Medicare beneficiaries with HIV/AIDS: risk of diabetes with protease inhibitors and associated racial disparities using big data approach

References

• 250, D. m. ICD-9data.com. http://www.icd9data.com/2014/Volume1/240-279/249-259/250/default.htm
   Google Scholar
• FOUNDATION, K. F. (2019). The HIV/AIDS Epidemic in the United States: The Basics. https://www.kff.org/hivaids/fact-sheet/the-hivaids-epidemic-in-the-united-states-the-basics/
   Google Scholar
• ICDdata.com. (2018a). Chronic viral hepatitis B with delta-agent. https://www.icd10data.com/ICD10CM/Codes/A00-B99/B15-B19/B18-/B18.1
   Google Scholar
• Abrahams, Z., Dave, J. A., Maartens, G., & Levitt, N. S. (2015). Changes in blood pressure, glucose levels, insulin secretion and anthropometry after long term exposure to antiretroviral therapy in South African women. Aids Research and Therapy, 12(1)), https://doi.org/10.1186/s12981-015-0065-8
   PubMedGoogle Scholar
• Almeida, S. E. d. M., Borges, M., Fiegenbaum, M., Nunes, C. C., & Rossetti, M. L. R. (2009). Metabolic changes associated with antiretroviral therapy in HIV-positive patients. Revista de Saude Publica, 43(2), 283–290. https://doi.org/10.1590/S0034-89102009005000005
   PubMed Web of Science ®Google Scholar
• Butt, A. A., McGinnis, K., Rodriguez-Barradas, M. C., Crystal, S., Simberkoff, M., Goetz, M. B., & Justice, A. C. (2009). HIV infection and the risk of diabetes mellitus. Aids (London, England), 23(10), 1227–1234. https://doi.org/10.1097/QAD.0b013e32832bd7af
   PubMed Web of Science ®Google Scholar
• Calza, L., Manfredi, R., Farneti, B., & Chiodo, F. (2003). Incidence of hyperlipidaemia in a cohort of 212 HIV-infected patients receiving a protease inhibitor-based antiretroviral therapy. International Journal of Antimicrobial Agents, 22(1), 54–59. https://doi.org/10.1016/S0924-8579(03)00100-6
   PubMed Web of Science ®Google Scholar
• Capeau, J., Bouteloup, V., Katlama, C., Bastard, J. P., Guiyedi, V., Salmon-Ceron, D., & Chene, G. (2012). Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment. Aids (London, England), 26(3), 303–314. https://doi.org/10.1097/QAD.0b013e32834e8776
   PubMed Web of Science ®Google Scholar
• Carr, A., Samaras, K., Thorisdottir, A., Kaufmann, G. R., Chisholm, D. J., & Cooper, D. A. (1999). Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study. Lancet, 353(9170), 2093–2099. https://doi.org/10.1016/s0140-6736(98)08468-2
   PubMed Web of Science ®Google Scholar
• Cheng, X., Yu, X., Ding, Y.-j., Fu, Q.-q., Xie, J.-j., Tang, T.-t., & Liao, Y.-h. (2008). The Th17/Treg imbalance in patients with acute coronary syndrome. Clinical Immunology, 127(1), 89–97. https://doi.org/10.1016/j.clim.2008.01.009
   PubMed Web of Science ®Google Scholar
• de Larrañaga, G. F., Petroni, A., Deluchi, G., Alonso, B. S., & Benetucci, J. A. (2003). Viral load and disease progression as responsible for endothelial activation and/or injury in human immunodeficiency virus-1-infected patients. Blood Coagulation & Fibrinolysis, 14(1), 15–18. https://doi.org/10.1097/00001721-200301000-00004
   PubMed Web of Science ®Google Scholar
• Echecopar-Sabogal, J., D'Angelo-Piaggio, L., Chaname-Baca, D. M., & Ugarte-Gil, C. (2018). Association between the use of protease inhibitors in highly active antiretroviral therapy and incidence of diabetes mellitus and/or metabolic syndrome in HIV-infected patients: A systematic review and meta-analysis. International Journal of STD & AIDS, 29(5), 443–452. https://doi.org/10.1177/0956462417732226
   PubMed Web of Science ®Google Scholar
• Gomes, A., Reyes, E. V., Garduno, L. S., Rojas, R., Mesejo, G. M., Del Rosario, E., & Donastorg, Y. (2016). Incidence of diabetes mellitus and obesity and the overlap of comorbidities in HIV+ hispanics initiating antiretroviral therapy. PloS one, 11(8), e0160797. https://doi.org/10.1371/journal.pone.0160797
   PubMed Web of Science ®Google Scholar
• Guwani, J. M., & Weech-Maldonado, R. (2004). Medicaid managed care and racial disparities in AIDS treatment. Health Care Financing Review, 26(2), 119–132.
   PubMedGoogle Scholar
• Harrington, L. E., Hatton, R. D., Mangan, P. R., Turner, H., Murphy, T. L., Murphy, K. M., & Weaver, C. T. (2005). Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages. Nature Immunology, 6(11), 1123–1132. https://doi.org/10.1038/ni1254
   PubMed Web of Science ®Google Scholar
• Hinkin, C. H., Hardy, D. J., Mason, K. I., Castellon, S. A., Durvasula, R. S., Lam, M. N., & Stefaniak, M. (2004). Medication adherence in HIV-infected adults: Effect of patient age, cognitive status, and substance abuse. AIDS (London, England), 18(Suppl 1), S19. https://doi.org/10.1097/00002030-200418001-00004
   PubMed Web of Science ®Google Scholar
• Hughes, C. A., Cashin, R. P., Eurich, D. T., & Houston, S. (2005). Risk factors for new-onset diabetes mellitus in patients receiving protease inhibitor therapy. The Canadian Journal of Infectious Diseases & Medical Microbiology, 16(4), 230–232. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2095027/ https://doi.org/10.1155/2005/971971
   PubMedGoogle Scholar
• ICDdata.com. (2018b). Chronic viral hepatitis C. https://www.icd10data.com/ICD10CM/Codes/A00-B99/B15-B19/B18-/B18.2
   Google Scholar
• Justman, J. E., Benning, L., Danoff, A., Minkoff, H., Levine, A., Greenblatt, R. M., & Anastos, K. (2003). Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. Journal of Acquired Immune Deficiency Syndromes, 32(3), 298–302. https://doi.org/10.1097/00126334-200303010-00009
   PubMed Web of Science ®Google Scholar
• Ledergerber, B., Furrer, H., Rickenbach, M., Lehmann, R., Elzi, L., Hirschel, B., & Weber, R. (2007). Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study. Journal of Biochemistry and Molecular Biology, 45(1), 111–119. https://doi.org/10.1086/518619
   Google Scholar
• Ngo-Metzger, Q., Mabry-Hernandez, I., Heslin, K., Weiss, A., Mummert, A., & Bierman, A. (2006). Characteristics of Inpatient Stays Involving Hepatitis C, 2005–2014: Statistical Brief# 232.
   Google Scholar
• Organization, W. H. (2006). Certain infectious and parasitic diseases: ICD Version 2007. http://apps.who.int/classifications/apps/icd/icd10online2007/index.htm?gb20.htm+
   Google Scholar
• Putcharoen, O., Wattanachanya, L., Sophonphan, J., Siwamogsatham, S., Sapsirisavat, V., Gatechompol, S., & Avihingsanon, Y. (2017). New-onset diabetes in HIV-treated adults: Predictors, long-term renal and cardiovascular outcomes. Aids (London, England), 31(11), 1535–1543. https://doi.org/10.1097/QAD.0000000000001496
   PubMed Web of Science ®Google Scholar
• Rasmussen, L. D., Mathiesen, E. R., Kronborg, G., Gerstoft, J., & Obel, N. (2012). Risk of diabetes mellitus in persons with and without HIV: A Danish nationwide population-based cohort study. PloS one, 7(9), e44575. https://doi.org/10.1371/journal.pone.0044575
   PubMed Web of Science ®Google Scholar
• ResDAC. (2020). Research Identifiable File Availability. https://www.resdac.org/file-availability
   Google Scholar
• Riyaten, P., Salvadori, N., Traisathit, P., Ngo-Giang-Huong, N., Cressey, T. R., Leenasirimakul, P., & Jourdain, G. (2015). New-Onset diabetes and antiretroviral treatments in HIV-Infected Adults in Thailand. Journal of Acquired Immune Deficiency Syndromes, 69(4), 453–459. https://doi.org/10.1097/qai.0000000000000647
   PubMed Web of Science ®Google Scholar
• Rosenbaum, P. R., & Rubin, D. B. (1985). Constructing a control group using multivariate matched sampling methods that incorporate the propensity score. The American Statistician, 39(1), 33–38. https://doi.org/10.1080/00031305.1985.10479383
   Web of Science ®Google Scholar
• Spagnuolo, V., Galli, L., Poli, A., Salpietro, S., Gianotti, N., Piatti, P., & Castagna, A. (2017). Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC Infectious Diseases, 17(1), 43. https://doi.org/10.1186/s12879-016-2099-5
   PubMedGoogle Scholar
• Squillace, N., Lorenzini, P., Lapadula, G., Bandera, A., Cozzi-Lepri, A., Rusconi, S., & Gori, A. (2016). Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 71(9), 2663–2669. https://doi.org/10.1093/jac/dkw185
   PubMed Web of Science ®Google Scholar
• Stephane De Wit, M., Worm, M., Reiss, P., Eric Fontas, M., Law, M. G., & PHD10, N. (2008). Incidence and risk factors for new-onset diabetes in HIV-infected patients. Diabetes Care, 31(6), 1224–1229. https://doi.org/10.2337/dc07-2013
   PubMed Web of Science ®Google Scholar
• Tien, P. C., Schneider, M. F., Cole, S. R., Levine, A. M., Cohen, M., DeHovitz, J., & Justman, J. E. (2007). Antiretroviral therapy exposure and incidence of diabetes mellitus in the Women's Interagency HIV study. Aids (London, England), 21(13), 1739–1745. https://doi.org/10.1097/QAD.0b013e32827038d0
   PubMed Web of Science ®Google Scholar
• Tripathi, A., Liese, A. D., Jerrell, J. M., Zhang, J., Rizvi, A. A., Albrecht, H., & Duffus, W. A. (2014). Incidence of diabetes mellitus in a population-based cohort of HIV-infected and non-HIV-infected persons: The impact of clinical and therapeutic factors over time. Diabetic Medicine, 31(10), 1185–1193. https://doi.org/10.1111/dme.12455
   PubMed Web of Science ®Google Scholar
• Tsiodras, S., Mantzoros, C., Hammer, S., & Samore, M. (2000). Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: A 5-year cohort study. Archives of Internal Medicine, 160(13), 2050–2056. https://doi.org/10.1001/archinte.160.13.2050
   PubMed Web of Science ®Google Scholar
• Wand, H., Calmy, A., Carey, D. L., Samaras, K., Carr, A., Law, M. G., & Committee, I. T. I. C. (2007). Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. Aids (London, England), 21(18), 2445–2453. https://doi.org/10.1097/QAD.0b013e3282efad32
   PubMed Web of Science ®Google Scholar
• Young, F., Critchley, J. A., Johnstone, L. K., & Unwin, N. C. (2009). A review of co-morbidity between infectious and chronic disease in Sub Saharan Africa: TB and diabetes mellitus, HIV and metabolic syndrome, and the impact of globalization. Globalization and Health, 5(1), 9. https://doi.org/10.1186/1744-8603-5-9
   PubMedGoogle Scholar
• Zhang, S., Senteio, C., Felizzola, J., & Rust, G. (2013). Racial/ethnic disparities in antiretroviral treatment Among HIV-Infected Pregnant Medicaid Enrollees, 2005–2007. American Journal of Public Health, 103(12), e46–e53. https://doi.org/10.2105/ajph.2013.301328
   PubMed Web of Science ®Google Scholar